Kefeng Xiao

Dr. Kefeng Xiao


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2019 in BJU International
Verified
Journal Article
Closed access
PDF file
ZYZhangqun Ye
Zhangqun Ye
GZGuohua Zeng
Guohua Zeng
HYHuan Yang
Huan Yang
JLJianxin Li
Jianxin Li
KTKun Tang
Kun Tang
HXHua Xu
Hua Xu

1 December 2018 in International Journal of Surgery
Verified
Journal Article
Closed access
JGJinan Guo
Jinan Guo
JFJiequn Fang
Jiequn Fang
XHXiangjiang Huang
Xiangjiang Huang
YLYanfeng Liu
Yanfeng Liu
YYYeqing Yuan
Yeqing Yuan
JWJianhong Wang
Jianhong Wang
The prognostic role of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in patients with prostate cancer (PCa) remains inconsistent. Here we quantify the prognostic impact of these biomarkers and assess their consistency in PCa. We systematically searched PubMed, Web of Science, and Embase for eligible studies embracing multivariate results. The Newcastle-Ottawa Scale were used to assess the study quality. Pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated. A total of 7228 patients from 18 studies were included in the meta-analysis. Overall, elevated pretreatment NLR was associated with poor overall survival (OS, HR 1.58, 95% CI 1.41-1.78, P < 0.001), progression-free survival (PFS, HR 1.95, 95% CI 1.53-2.49, P < 0.001) and biochemical recurrence-free survival (BRFS, HR 1.37, 95% CI 1.07-1.75, P = 0.011). And high pretreatment PLR was correlated with more inferior PFS (HR 1.62, 95% CI 1.20-2.19, P = 0.002), OS (HR 1.70, 95% CI 1.34-2.15, P < 0.001) and cancer-specific survival (CSS, HR 2.02, 95% CI 1.24-3.29, P = 0.005). Moreover, the subgroup analyses did not alter the direction of results for OS and PFS. Based on these findings, elevated NLR and PLR was associated with poor oncologic outcomes, and they can serve as prognostic factors in PCa patients.

6 June 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
GZGuohua Zeng
Guohua Zeng
TZTao Zhang
Tao Zhang
MAMadhu Agrawal
Madhu Agrawal
XHXiang He
Xiang He
WZWei Zhang
Wei Zhang
KSKemal Sarıca
Kemal Sarıca

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JPJunming Peng
Junming Peng
HJHongtao Jiang
Hongtao Jiang
JGJinan Guo
Jinan Guo
JHJiansheng Huang
Jiansheng Huang
QYQian Yuan
Qian Yuan
KXKefeng Xiao
Kefeng Xiao
Purpose. CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily. Mature CD147 is an N‐linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors. However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated. Methods. The study included 159 patients with BC and 68 healthy controls. The expression of CD147 and gasdermin D (GSDMD) was analyzed by immunohistochemistry (IHC). Western blotting was performed to detect the expression of proteins in BC cells. The relationship between CD147 and GSDMD was analyzed by the IHC score. Results. The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki‐67, which is a cell proliferation antigen. In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki‐67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation. Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation. BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate. Conclusion. These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.

1 January 2014 in Asian Journal of Andrology
Verified
Journal Article
Open access
PDF file
YLYu Liu
Yu Liu
JYJiang-Gen Yang
Jiang-Gen Yang
HJHONGTAO JIANG
HONGTAO JIANG
QYQian Yuan
Qian Yuan
ZLZeng-Qin Liu
Zeng-Qin Liu
KXKefeng Xiao
Kefeng Xiao
The aim of this study was to evaluate the outcomes of multiple advanced surgical treatments (i.e. microsurgery, laparoscopic surgery and endoscopic surgery) for acquired obstructive azoospermia. We analyzed the surgical outcomes of 51 patients with suspected acquired obstructive azoospermia consecutively who enrolled at our center between January 2009 and May 2013. Modified vasoepididymostomy, laparoscopically assisted vasovasostomy and transurethral incision of the ejaculatory duct with holmium laser were chosen and performed based on the different obstruction sites. The mean postoperative follow-up time was 22 months (range: 9 months to 52 months). Semen analyses were initiated at four postoperative weeks, followed by trimonthly (months 3, 6, 9 and 12) semen analyses, until no sperm was found at 12 months or until pregnancy was achieved. Patency was defined as >10,000 sperm ml−1 of semen. The obstruction sites, postoperative patency and natural pregnancy rate were recorded. Of 51 patients, 47 underwent bilateral or unilateral surgical reconstruction; the other four patients were unable to be treated with surgical reconstruction because of pelvic vas or intratesticular tubules obstruction. The reconstruction rate was 92.2% (47/51), and the patency rate and natural pregnancy rate were 89.4% (42/47) and 38.1% (16/42), respectively. No severe complications were observed. Using multiple advanced surgical techniques, more extensive range of seminal duct obstruction was accessible and correctable; thus, a favorable patency and pregnancy rate can be achieved.

1 March 2018 in Anticancer Research
Verified
Journal Article
Open access
PDF file
JGJinan Guo
Jinan Guo
JYJianggen Yang
Jianggen Yang
XZXuhui Zhang
Xuhui Zhang
XFXiaoyan Feng
Xiaoyan Feng
HZHeqiu Zhang
Heqiu Zhang
KXKefeng Xiao
Kefeng Xiao
Background/Aim: Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. This study intended to identify a biomarker panel to distinguish PCa from benign prostate using urine samples. Materials and Methods: We identified six biomarkers with differential gene expression in 154 PCa and benign prostate specimens. We then determined mRNA expression signature and the diagnostic performance of the 6-biomarker panel in 156 urine samples from patients with PCa and benign disease. Results: The 6-biomarker panel distinguished PCa from benign prostate cases with sensitivity of 80.6%, specificity of 62.9% and area under the curve (AUC) of 0.803 (p<0.0001), whereas serum PSA at 4 ng/ml cutoff had sensitivity of 95.5%, specificity of 20.2% and AUC of 0.521 (p<0.0001). Conclusion: The 6-biomarker panel for use in urine samples was able to distinguish PCa from benign prostate with higher specificity and accuracy than PSA and may be useful in clinical settings.